Category: Clinical Data
PharmaSignal — Clinical Data
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
Pharmaceutical Technology
KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy.
Viridian reports positive results from elegrobart phase 3 trial
PharmaTimes
Company says treatment shows strong efficacy and convenient dosing profile
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Pharmaceutical Technology
Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.
ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose
Pharmaceutical Technology
At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF.
ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit
Pharmaceutical Technology
At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key biomarke
Viridian tumbles on positive data for key eye drug prospect
BioPharma Dive
The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
BioSpace
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
BioSpace
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline
BioSpace
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunol
AstraZeneca lung drug gets ‘surprise’ win in COPD trials
BioPharma Dive
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
BioPharma Dive
Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.
Maze tumbles despite positive data for kidney disease drug
BioPharma Dive
Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.
Beam posts positive data on base editing treatment for AATD
BioPharma Dive
Updated data showed the biotech’s approach to the rare lung and liver condition helped restore functional protective proteins in a small study.
Sarepta sees early success with RNAi drugs from Arrowhead
BioPharma Dive
Long-awaited results from Phase 1/2 studies lifted Sarepta s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.
Karyopharm myeloma drug yields mixed data in myelofibrosis trial
BioPharma Dive
Xpovio combined with Incyte s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst s estimates, could triple the company s revenue.
Apogee strengthens case for longer-lasting eczema drug
BioPharma Dive
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.